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1. Introduction 
The Human Immunodeficiency Virus-1 (HIV-1), the causative agent of the acquired 
immunodeficiency syndrome (AIDS), was described for the first time in 1983 [1, 2]. In the 
meantime, various classes of anti-retroviral drugs have been developed and combination 
therapy has improved the quality of life for millions of people affected. At the end of 2010 
more than 34 million people were living with HIV infection worldwide [3]. Despite the 
increased access to antiretroviral therapy, an extensive treatment gap persists between the 
low-/middle-income countries and well-developed ones. This resulted in 1.8 million HIV 
related deaths and 2.6 million newly infected persons in 2009 [3]. Even for those who have 
access to treatment, there is no cure, as current therapy regimens cannot eradicate the virus. 
Therefore, the control and ultimate eradication of this pathogen remains one of the most 
important challenges in today’s biomedical research. 
HIV belongs to the family of Retroviridae and the genus Lentivirus (lenti, Latin for “slow”), 
which is characterized by a long incubation period causing long-lasting illnesses [4]. An HIV 
particle has a spherical shape and a size of about 100 nm. It consists of an outer coat, called 
the viral envelope, and an inner capsid enclosing two copies of positive single stranded 
ribonucleic acid (RNA). The RNA genome is 9.5 kB large and is composed of nine genes 
encoding structural (Gag, Pol and Env), regulatory (Tat and Rev) and accessory (Nef, Vif, 
Vpr and Vpu) proteins [5]. HIV-1 mainly infects CD4+ cells such as CD4+ T cells, 
macrophages and dendritic cells (DCs). Infection is initiated by the binding of the viral 
envelope glycoprotein 120 (gp120) to the CD4 receptor of the host cell, resulting in a 
conformational change that allows gp120 to interact with one of the co-receptors, CCR5 or 
CXCR4.  
Binding of gp120 to the co-receptor induces further conformational changes that lead to the 
exposure of the fusion domain on glycoprotein 41 (gp41). Fusion of this domain with the 
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lipid cell membrane allows entry of the viral core into the host cell cytoplasm. This is 
followed by reverse transcription of the single-stranded RNA into double-stranded DNA, 
which becomes integrated into the host genome [6]. After DNA integration, HIV remains 
present as a latent DNA provirus which becomes active upon cell activation [7]. 
Transcription of the viral proteins eventually leads to the formation of mature and infectious 
virions [8]. 
HIV-1 can be transmitted “horizontally” through hetero- or homosexual contact or blood-
blood contact (e.g. blood transfusion or intravenous drug use) as well as “vertically” from 
mother-to-child [9]. The transmission of HIV strongly depends on the concentration of virus 
in the body fluids (genital secretions, plasma or breast milk), viral “fitness” properties and 
the host susceptibility at both the immunological and the cellular level [10].  
Clinically, an HIV-1 infection course can be divided in three stages: the primary or acute 
infection phase, the chronic phase (first asymptomatic and later non-AIDS defining 
symptoms) and the terminal AIDS defining illness. The first days after infection, the virus 
spreads from the portal of entry via regional lymph nodes throughout the body. It readily 
infects CD4+ T cells, producing new virions, which results in a high plasma viral load (VL). 
The virus finds its way to all lymphoid organs, but with a particularly massive viral 
production by the gastro-intestinal associated lymphoid tissue (GALT) is often observed. 
Remarkably, only a proportion of the newly infected patients experiences a clinical “acute 
phase syndrome”, characterized by mononucleosis- or flu-like symptoms, including fever, 
fatigue, sore throat, skin rash, enlarged lymph nodes, diarrhea, nausea and general malaise. 
In the first three to six weeks a rapid decline of CD4+ T cells is observed in the peripheral 
blood and even more pronounced in the GALT, which nonetheless remains an important 
HIV reservoir [11]. The appearance of HIV-1 specific cellular immune responses and the 
subsequent production of HIV-1 specific antibodies results in a sharp drop of viral load 
reaching a steady state viraemia, called the viral setpoint (usually within six months after 
infection). A dynamic equilibrium is then established between viral replication (fitness) and 
viral suppression by the immune system. Nevertheless, because of the limited regeneration 
capacity of the immune system (including thymic atrophy in adults) the number of CD4+ T 
cells will continue to gradually decrease during the chronic phase. This stage can last up to ten 
years and is characterized by lack of clinical symptoms of illness or relatively mild symptoms 
that often do not raise suspicion of HIV infection. Eventually the immune system becomes 
exhausted due to chronic immune activation and T-cell depletion as a result of direct 
cytopathic effects of infected cells, but even more by induction of apoptosis of uninfected 
bystander cell (CD4+ and CD8+ T cells) and degeneration of lymphoid organs. Opportunistic 
diseases, including serious infections or malignant tumors that are no longer controlled due to 
a loss of immune surveillance are the cause of AIDS-related deaths [10, 12, 13]. 
The majority (> 90 %) of infected individuals progresses to AIDS within about ten years after 
primary infection (normal progressors). Some individuals (around 5 %) remain 
asymptomatic for more than ten years with stable numbers of CD4+ T cells and low to 
intermediate viral loads (long term survivors and long term non progressors) [14]. Less than 
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1 % of infected individuals have viral  loads below 50 copies per ml for at least 1-2 years 
while untreated (elite controllers or HIV controllers) [15]. Some individuals remain 
uninfected, despite being highly exposed to HIV-1 (exposed seronegatives) [16]. 
The first effective antiretroviral drugs (all nucleoside analogues) became available at the end 
of the nineties. They were used in single and later in dual combinations, but could suppress 
the viral load (VL) only temporarily. This was due to the appearance of drug resistance [17]. 
Triple drug combinations called “highly active antiretroviral therapy” (HAART), are able to 
suppress VL in a more sustained way and hence can prevent the emergence of drug 
resistance. For a number of years viral suppression was only possible at the cost of a high 
medication burden and many side effects. During the last decade, however, HAART has 
become less complicated and better tolerated, which has converted HIV-1 infection into a 
chronic but treatable disease [18].  
It should be kept in mind, however, that HAART is not a treatment devoid of shortcomings. 
Firstly, a life-long commitment to the therapy remains mandatory to keep the virus under 
control and delay disease progression. Secondly, the treatment may cause toxic drug-related 
adverse effects such as cardiovascular complications [19], renal and hepatic diseases [20], 
lipodystrophy and diabetes mellitus, collectively called “metabolic syndrome” [21]. Thirdly, 
even though HAART restores the number of circulating CD4+ T cells to near normal levels, 
responses against HIV itself remain deficient [11, 22]. Finally, this costly treatment is not 
available for all infected persons, especially not in low- and middle-income countries in 
Africa, Asia and Latin America, where the numbers of patients are the highest and still 
increasing [3]. 
Therefore, there is a clear need for cheaper and more widely available therapies that can 
suppress and/or eliminate the viral reservoir even if the treatment is stopped or interrupted. 
Improving HIV-specific cell-mediated immunity by therapeutic vaccination is a generally 
accepted approach to tackle the problem.  
During the last decade immunotherapeutic vaccination strategies have been sought after to 
boost the immune system in order to control virus replication and to eliminate infected cells. 
These vaccines are largely based on ex vivo loading of dendritic cells with antigens and 
immune-stimulating molecules. This personalized process is time-consuming, labor 
intensive, and requires strict quality control. It should be stressed that high costs of the 
procedure together with the need to use sophisticated equipment, restrains its application in 
less developed countries.  
Recently, particulate antigen vehicles have been introduced in the field of vaccine design 
with the purpose to improve antigen delivery and to induce antigen specific immune 
responses. A variety of nano- and micro-carriers has been developed to deliver protein, 
peptides and/or nucleic acids to cells of the immune system. The intracellular fate of these 
particles depends on their physicochemical characteristics such as size, stability and charge. 
These in turn determine the efficiency with which the specific cargo is delivered to antigen-
presenting cells (APC) and the extent of antigen-specific immune responses induced. 
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2. HIV and the immune system 
2.1. Immune activation 
Chronic HIV-related immune activation is characterized by the inappropriate production of 
pro-inflammatory cytokines and overexpression of cellular activation and exhaustion 
markers. Most of these inflammatory responses induced by HIV are not directed toward 
HIV. They rather enhance susceptibility of target cells to HIV infection and enhance virus 
replication in already infected cells, which accelerates disease progression. This chronic, 
non-specific T cell activation leads to T cell exhaustion and apoptosis of CD4+ and CD8+ T 
cells [23]. Increased expressions of HLA-DR and CD38 molecules on CD8+ T cells correlate 
with a higher level of immune activation and constitute markers for bad prognosis, which 
are partly independent from actual CD4 T count and VL [24]. 
It remains unclear whether there is a single key mechanism behind this HIV-associated 
immune activation. A so-called “leaky gut syndrome” hypothesis proposes that massive loss 
of CD4+ T cells in the GALT may affect the protective barrier of the intestinal mucosa, 
allowing bacterial toxins such as lipopolysaccharide (LPS) to enter the bloodstream [25]. 
This “microbial translocation” could in consequence induce a pathological over-activation of 
both the innate and adaptive immune system. Another hypothesis puts more emphasis on 
intrinsic regulation of type I interferon (IFN) [26]. It has been shown indeed that patterns of 
type I IFNs produced by plasmacytoid DCs (pDCs) are different in non-pathogenic SIV 
infections of natural hosts (like sooty mangabeys, African green monkeys and mandrills) 
and pathogenic SIV infections of rhesus macaques. High and robust type I IFN responses 
are observed in natural hosts during acute infection. Expression of type I IFNs is, however, 
down-regulated during the chronic infection phase. By contrast, the type I IFNs are 
persistently produced in SIV infected rhesus macaques [27]. Sooty mangabeys, the natural 
hosts of SIV, show no immune activation and rarely progress to AIDS, despite high levels of 
virus replication and severe CD4+ T cell depletion in the GALT. In contrast, rhesus 
macaques, infected with the same or closely related SIV, progress to AIDS [28].  
Another enigma remains the role of CD25 and forkhead box (FOX) P3 expressing regulatory 
CD4+ T (Treg) cells. On the one hand, they may suppress chronic immune activation. On the 
other hand, they could undermine the effective T cell responses [29]. It has been shown that 
the number of Treg cells increases in the GALT, but not in the peripheral blood, during HIV 
infection in untreated individuals [30]. Whether this accumulation of Treg cells delays 
disease progression by inhibition of immune activation or increases the susceptibility of the 
gastrointestinal tract to opportunistic infections remains a matter of debate [29].  
2.2. HIV-specific humoral immune response 
The humoral immune response is mediated by antibody producing B cells (figure 1). In 
general, by preventing infections of the host cells, virus-specific antibodies play an 
important role in the control of many viral infections [31]. This arm of the adaptive immune 
system is activated after uptake of viral proteins by antigen presenting cells (DCs, 
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macrophages and B cells) that digest the proteins into small peptides and present them on 
MHC II molecules to CD4+ T helper (Th) cells. Specifically activated Th2 cells that produce B 
cell stimulating cytokines (including IL-4, IL-5, IL-6, IL-10, TGF−β) will activate naive B cells. 
The latter are recognized by specific epitopes or intact virus through their surface IgM and 
promote B cell differentiation into plasma cells producing large amounts of IgG, IgA, IgE 
antibodies and memory B cells. During HIV-1 infection antibodies against gp120, gp41, the 
nucleocapsid (p24) and the matrix (p17) arise few weeks to several months after infection. 
This process is commonly referred to as seroconversion.  
 
 
Figure 1. Overview of the adaptive immune responses after virus recognition by antigen presenting 
cells. Virus antigens are presented by dendritic cells and B cells to T cells. Infected cells present peptides 
together with MHC I molecules on the plasma membrane. The peptide-MHC I complex is recognized 
by precursor cytotoxic CD8+ T lymphocytes (CTLs). Th1 cells, induced by antigen presenting cells, 
produce IL-2, IFN-γ, and TNF-α. This results in activation and differentiation of the precursor CTLs 
into memory or effector CTLs. Effector CTLs can directly kill infected cells by the production of 
perforines and granzymes. Activated Th2 cells, also induced by antigen presenting cells, produce B cell 
stimulating cytokines (including IL-4, IL-5, IL-6, IL-10, TGF−β) that activate naive B cells. This 
facilitates/induces B cell differentiation into memory B cells and plasma cells that produce large 
amounts of IgG, IgA, IgE antibodies that prevent further virus infection. Ab: antibody, Ag: antigen, 
APC: Antigen Presenting Cell, DC: Dendritic Cell, IL: Interleukin, TCR: T Cell Receptor, Th: CD4+ T 
helper cell. 
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The virus neutralization is characterized by the interaction of specific antibodies with the 
viral envelope spikes. This interferes with virus attachment or viral entry in target cells and 
results in the inhibition of infection. Only a minority of anti-HIV Env antibodies, at any 
time, exerts immune pressure by autologous neutralization. However, the virus easily 
mutates and readily escapes from these potentially protective immune responses [32]. 
During the chronic course of infection only 20% of the infected individuals will generate 
broadly neutralizing antibodies (bNAbs) having the ability to neutralize heterologous 
viruses [33]. In addition to classical neutralization, antibodies can attach to HIV infected 
cells and kill them via antibody dependent cellular cytotoxicity (ADCC) mediated through 
their Fc moiety and natural killers cells (NK) [34, 35].  
2.3. HIV-specific cellular immune response 
The cellular immune response is the other arm of the adaptive immune system (figure 1) 
and it is crucial to combat viral infections. CD8+ cytotoxic T lymphocytes (CTLs), which 
eliminate infected cells, play a key role in this process. The initial step involves processing of 
intracellular antigens by the proteasome. The resulting peptides are then presented together 
with MHC I molecules on the membrane of infected somatic cells. The peptide-MHC I 
complex is recognized by precursor cytotoxic CD8+ T lymphocytes (CTLs). Also in that case 
a CD4+ T cell help, induced by antigen presenting cells, is crucial. In this case so-called Th1 
cells, producing IL-2, IFN-γ, and TNF-α, activate and differentiate the CTLs into memory or 
effector CTLs. Effector CTLs can directly kill infected cells by the production of perforines 
and granzymes (figure 2) [36]. Alternatively, CTLs can induce apoptosis of the infected cells 
after interaction of Fas ligand on CTLs with Fas receptor on infected T cells [37]. CD8+ T cells 
also display a non-cytotoxic antiviral activity involving several cytokines, chemokines and a 
yet unidentified soluble CD8+ cell antiviral factor (CAF) [38].  
 
Figure 2. HIV-induced T cell responses. HIV specific CD8+ effector cells produce chemokines and 
cytokines in order to eliminate infected cells. CD4+ T helper cells help to stimulate both dendritic cells 
and CD8+ T-cells to maintain a CD8+ T-cell memory response. HIV interferes with this supportive 
function of CD4+ T-cells. 
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The first T cell responses during HIV infection arise when the viraemia peak is approached 
and reach maximum 1-2 weeks later. In non-controllers, the virus  evades the CD8+ 
mediated T cell response by introducing mutations in CTL epitopes [39], by Nef-mediated 
down-regulation of MHC I and by influencing cytokine production and T-cell signaling [40]. 
Since an optimal CD8+ T cell response, similar to the B cell response, depends on help of 
CD4+ T lymphocytes, the deterioration of CD8 mediated viral control is also related to the 
weakening of CD4+ T cell function [41, 42]. 
There are many indications that HIV-specific CD8+ T cell responses are responsible for at 
least partial VL control. In the macaque model, depletion of CD8+ T cells during SIV- 
infection resulted in an increased viral load [43, 44]. In HIV-infected human subjects, who 
initially control the virus, escape mutations in specific CD8+ T cell epitopes were responsible 
for the loss of control and increase in VL [45, 46].  
3. Correlates of protection 
To date no definite biological markers have been unambiguously shown to correlate with 
patients’ ability to control HIV infection by suppressing virus production and eliminating 
infected cells. Defining these factors would be crucial for the development of preventive and 
therapeutic vaccination strategies. For that reason, research groups focusing on preventive 
vaccines carefully study individuals that can avoid infection (exposed seronegatives) or 
partly control the virus load without the need of HAART. 
3.1. Natural resistance and genetic factors of the host 
Individuals that have the homozygote deletion Δ32 in co-receptor CCR5 are largely resistant 
to HIV-1 infection [47]. It has been recently reported that an HIV patient, who received 
CCR5 Δ32/Δ32 stem cells for transplantation, remained without viral rebound for several 
years [48, 49]. 
Certain intracellular molecules, expressed by the host, can at least partly protect against 
cellular infection or virus release. The most important factors identified so far are 
APOBEC3G, APOBEC3F, TRIM5α and tetherin. APOBEC3G is a cytosine deaminase that 
incorporates adenosine instead of guanosine during synthesis of the viral DNA, which 
results in defective proviral DNA [50]. In addition APOBEC3G promotes natural killer cell-
mediated lysis [51]. Individuals expressing large amounts of APOBEC3G have lower viral 
loads during acute infection phase [52]. TRIM5a binds to the viral capsid, blocking 
replication early in the viral life cycle [53]. Tetherin interferes with the virion release by 
attaching the mature virions to each other and to the host membrane [54]. 
Certain polymorphisms in the human leukocyte antigen (HLA type) and T or NK cell 
receptor can affect the cellular HIV-specific immune responses. It has been shown that 
human leukocyte antigens B*27, B*57 and B*58 are associated with better control of HIV-1 
and slower disease progression [55-57]. Interestingly HLA B*57 also plays a role in the 
innate protective immune responses, acting as a natural ligand for inhibitory killer 
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immunoglobulin-like receptors (KIRs). KIR3DL1 and KIR3DS1 are also associated with 
delay in disease progression [58, 59]. 
3.2. Suggested immune correlates 
High and broadly neutralizing antibody titers at the port of the virus entry are likely 
essential to prevent (new) infections of host cells. Indeed high levels of HIV-neutralizing IgA 
were detected at mucosal surfaces of some exposed seronegative individuals [60-62]. 
Moreover, in several models of transmission, passive immunization with neutralizing 
monoclonal antibodies could protect macaques from infection. In contrast, once infection 
has been established, neutralizing antibodies seem to be unable to control the virus spread 
[63]. In order to eliminate infected cells, strong CD8+ T cell responses seem to be of 
importance. As already discussed, most infected individuals show strong CD8+ T cell 
responses in reaction to the first viraemia peak, resulting in a decline of the viral load in 
early infection. Unfortunately, in most cases (except for elite controllers) these responses are 
not able to maintain full control, mainly due to iterative immune escape [39] and chronic 
immune activation [23], ultimately resulting in T cell exhaustion [64]. In contrast, HIV-
specific CD8+ T cells preserve their function and new effective CD8+ T cell responses can 
arise against viral escape variants in elite controllers [55]. Additionally, a strong avidity of 
the T cell receptor for the epitope-MHC-I-complex has been shown to promote 
polyfunctional CD8+ T cells [65] and to initiate more rapid lysis of the target cell [66, 67]. 
Furthermore, the presence of polyfunctional CD8+ T cells, that have the capacity to exert 
different effector functions by producing IFN-γ, TNF-α, IL-2, MIP-1β, perforines and/or 
granzymes and to proliferate upon antigen stimulation, has been associated with the 
“controller” status [68, 69]. Another important observation came from the study of 
Geldmacher and colleagues who reported that responses directed against Gag epitopes are 
dominant and potentially protective in long term non progressors  and elite controllers [70]. 
One of the reasons for this observation could be escape mutations, in particular HLA-
restricted epitopes of Gag, that come at a cost of great loss in viral fitness [71-73]. 
As already explained, maturation and differentiation of CD8+ T cells into functional memory 
and effector subsets are also dependent on functional CD4+ T helper cells. The remaining 
CD4+ T cells, after massive depletion during acute infection, need to be polyfunctional by 
producing at least both IFN-γ an IL-2 in order to proliferate upon antigen stimulation [41] 
and provide help to CTL. This Th1 function is impaired in HIV non-controllers [74]. 
Unfortunately, none of these factors can truly predict protection against HIV infection [75]. 
Therefore, at present it seems wise to conclude that all potential correlates (table 1) should 
be taken into account while designing HIV therapies. This includes the preservation of 
functional Th1 HIV-specific CD4+ T cells and the availability of central memory and memory 
effector HIV-specific CD8 T cells, with strong avidity for particular difficult-to-mutate 
epitopes. In addition also a broad functional activity, including production of several 
effector cytokines and lytic factors are important to result in high and broad HIV-
suppressive immune responses [75].  
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Level of protection Suggested correlates of protection
Viral factors Deletion in Nef [76] 
Host genetic factors CCR5 D32/D32 [48, 49] 
Host restriction factors High levels of antiviral fator APOBEC3G [51, 52] 
High production of TRIM5α [53] 
Up-regulation of tetherin [54] 
HLA types B*27, B*57, B*58 [55, 56] 
KIR3DL1, KIR3DS1 [58, 59] 
Humoral immunity Neutralizing Abs: IgA antibodies at the mucosal surfaces [60-63] 
Cellular immunity Polyfunctional T cells [66, 69] 
Proliferative CD4+ and CD8+ T cells [68, 70] 
  Avidity of HIV specific T cell responses [65, 66, 74] 
Table 1. Suggested correlates of protection. 
4. Vaccination strategies against HIV-1 
Many infection-related hurdles complicate the development of an HIV vaccine. These 
include the high genetic variability, the potential of cell-to-cell transmission and other 
evasion strategies such as down-regulating MHC I in infected cells and latency of the virus 
[77]. In addition, correlates conferring protection against HIV remain to be established. A 
number of potential markers have been suggested to prevent or control HIV infection. These 
comprise: production of high titers of neutralizing antibodies with broad specificities, 
concomitant HIV-specific activation of CD4+ and CD8+ T cells, polyfunctional T cell 
responses (production of several immune mediators by the same T cell) and induction of 
long- term memory cells [78]. 
4.1. Prophylactic vaccines  
Prophylactic vaccines rely on the production of antibodies that bind to free virus particles 
thereby preventing viral entry into host cells (defined as neutralization) and thus block 
infection. Vaccines are designed to mimic natural infections, by using live-attenuated virus 
(measles, mumps), chemically inactivated virus (polio) or recombinant subunits of the virus 
(Hepatitis B). There is circumstantial evidence that neutralizing antibodies could play a role 
in the protection against HIV. HIV-neutralizing IgA antibodies have been isolated in 
frequently exposed individuals, who remained uninfected [62, 79]. In addition, passive 
immunization with several HIV neutralizing IgG monoclonal antibodies protects macaques 
against infectious SHIV (simian immune deficiency virus with an HIV envelope) [80, 81]. 
Although attenuated SIV vaccines provided some level of protection against super-infection 
in macaques, attenuated HIV is considered too risky to be ever tried in humans [82]. 
Therefore, much effort has been invested in the development of subunit vaccines that could 
elicit production of neutralizing antibodies. It should be taken into account that broadly 
neutralizing antibodies (bNAbs) that inhibit also heterologous viruses in vitro, can be 
detected in 20% of naturally infected individuals. This implies that the production of these 
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antibodies is not sufficient to provide full protection against established HIV, but could still 
be efficient in prevention of cell-free transmission. The most important reason why it is 
difficult to induce bNAbs is the extreme variability of HIV Env antigenic epitopes. 
Moreover, the virus is shielded by non-immunogenic glycans, which hinder binding of 
antibodies to the envelope proteins [83, 84]. Due to these problems, prophylactic vaccine 
trials in humans have failed to elicit protection. The only exception till now is the recent 
Thai vaccine trial (RV144).  
Nevertheless neutralizing antibodies with activity against easy-to-neutralize so-called “Tier 
1” viruses have been induced in a number of animal trials, but these antibodies failed to 
broaden and faded rapidly, even upon repeated heterologous boosts [85]. The failure to 
induce high titers of NAbs moved the field towards strategies aiming at stimulating 
polyfunctional and sustained CD4+ T help responses [69] to support high quality cytotoxic T 
cells (both central memory and effector memory). These cells would be necessary to rapidly 
eliminate infected cells, if antibodies fail to prevent cellular infection [86, 87]. This “second 
line prevention” hypothesis was further supported by the observations that HIV-specific 
CD4+ and/or CD8+ T cells as well as particular human leukocyte antigen (HLA) class I 
markers, and not antibodies, correlate with resistance to HIV in some highly exposed 
seronegative children (potential vertical transmission) [88] or women (potential heterosexual 
transmission) [89-91]. 
In this connection, current HIV vaccines are also aiming at the induction (prophylactic field) 
or enhancing (therapeutic field) of HIV specific T cell responses. Such vaccines would elicit 
or boost HIV specific cytotoxic T cells (CTLs) to eliminate infected cells and CD4+ T cells, 
which can help to induce and maintain B cell and CD8+ T cells responses [92]. Several 
strategies are currently under investigation to establish effective T cell responses in either a 
preventive or therapeutic setting either based on protein [93, 94] or peptide [95] 
vaccinations, virus like particles (VPLs) [96], DNA vaccination using viral vectors [97, 98], 
prime-boost vaccinations [99, 100] or DC-based vaccines [101-109]. 
4.2. Viral vaccine delivery 
Whereas the use of live attenuated HIV is considered to be unsafe for the use in humans, the 
development of vaccines based on HIV-inactivated with formalin is compromised by the 
fact that the antigenicity of the envelope gets lost. Milder formalin treatment of the virus, 
followed by heat-inactivation has been shown to circumvent this hurdle and induce modest 
neutralizing antibodies titer in non-human primates [110].  
During the last decade, a variety of vaccines was designed using (plasmid) DNA/RNA 
vaccine candidates for priming followed by live vectored recombinant vaccines for 
boosting, some of which have already been tested in advanced stages of clinical trials [111, 
112]. We will highlight here some of the specific characteristics of viral vectors, which 
have been used in preclinical and early clinical preventive vaccinations against SIV and 
HIV, respectively. 
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Adenoviruses, poxviruses and lentiviruses are the most frequently used viral vector 
systems. The major advantages of these vectors are the high transduction efficiency 
resulting in high level expression of the encoded protein and the possibility to target specific 
cells achieved by altering the viral tropism (e.g. by pseudotyping with envelope or counter 
receptors of another virus) [113, 114]. Major drawbacks are the high risk of insertional 
mutagenesis, high production cost of large amounts high-titered viral stocks and a limited 
size of nucleic acids that can be packed [113, 114]. The first trial of a preventive HIV vaccine 
that was designed to elicit a strong cellular immune response was the STEP trial done by 
Merck. It involved immunization of almost 3000 healthy uninfected volunteers with three 
recombinant adenovirus serotype-5 (rAD5) vectors, Ad5-gag, Ad5-pol and Ad5-nef. 
Unfortunately, it failed to induce protection against infection [115, 116]. Moreover, the 
vaccine increased the rate of HIV infection in individuals with pre-existing immunity to 
adenoviruses [117]. The exact mechanism that underlies this phenomenon remains to be 
elucidated, but it has been suggested that the activation of pre-existing vector specific T cells 
may have increased numbers of HIV target cells. This might be avoided by the use of less 
prevalent adenovirus serotypes (e.g. Ad11, Ad24 or Ad35) instead of the Ad5 vector in 
designing future HIV vaccines [118, 119]. 
Alternatively, poxvirus-based vectors should be taken into account since they do not pose 
any problems with pre-existing immunity. In addition, they are used as highly attenuated 
vaccinia virus strains. Three of the best characterized highly attenuated pox vectors are the 
recombinant viral canary pox vectors such as the highly attenuated vaccinia virus strain 
ALVAC [120], the recombinant modified vaccinia Ankara (MVA) vectors [121-123] and 
canarypox-derived NYVAC [120, 124, 125]. Recombinant pox vectors, encoding HIV 
antigens, have been shown to be safe in humans and to induce HIV specific immune 
responses. No protection against HIV infection has been achieved with the exception of the 
preventive RV144 phase III clinical trial. In this clinical trial, involving 16 000 uninfected 
individuals, a canary pox vector coding HIV Gag and Env was used as prime immunization 
followed by a recombinant Env gp120 protein boost (RV144). A 31% efficacy of protection 
against HIV infection was demonstrated after three years [126]. Very recently, Barouch et al. 
reported that rhesus monkeys, receiving heterologous vector regimes (adeno with MVA), 
were protected with an efficacy of 80% after SIV challenges [127]. 
Another type of vectors that could avoid the pre-existing immunity issue is based on 
lentiviruses. These vectors have been explored extensively in the field of gene therapy since 
they efficiently transduce non-dividing cells, such as DCs [128, 129], and promote long term 
antigen expression [130]. Lentiviral vector vaccines have been shown to induce both high 
short term and long-term anti-HIV immune responses in mice [131, 132]. Even in the 
absence of circulating CD4+ T cells, induction of specific CTLs was obtained [133]. Despite 
reassuring safety and tolerability results in a phase I clinical trial [134], the major concern 
remains the risk of insertional mutagenesis [135]. Attempts to overcome this risk, have led to 
the design of self-inactivating vectors, vectors with targeted integration and non-integrating 
vectors [135]. 
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Replicating and persistent recombinant cytomegalovirus (CMV) vectors have recently been 
shown to be a promising system in rhesus macaques [136]. Prophylactically vaccinated 
animals maintained CD4+ and CD8+ T effector memory (TEM) cell responses, regardless to 
pre-existing CMV immunity, and were more resistant to challenge than the control group 
even in the absence of neutralizing antibodies [137]. The authors suggest that TEM responses 
are crucial in the protection against HIV infection after sexual exposure. This is obviously 
also the scope of HIV immunotherapy where sustained effector and memory T cells can 
eliminate infected cells. 
Virus-like-particles (VLPs) have recently emerged as novel delivery systems. They contain 
envelope and core proteins from SIV/HIV in their native structure. These pseudo-virions are 
produced in baculovirus or vaccinia virus expression systems where Gag and Env proteins 
from HIV or SIV are co-expressed and spontaneously assembled. The immunogenicity of 
these vaccines was only modest in non-human primates [96], however, efficiency was 
greatly improved when combined with a HIV DNA vaccine prime [138].  
Safety concerns and difficulties related to repeated administrations of viral vectors that may 
evoke dangerous immune reactions are the most important bottlenecks in regard to clinical 
application in humans. To improve the general safety profile and circumventing the 
drawbacks inherited to viral delivery, well-defined particulate vaccines have emerged as 
promising candidates in the field of vaccine development. 
5. HIV Immunotherapy with DC-based vaccines 
5.1. Therapeutic vaccines 
Since the introduction of HAART, HIV-1 infection has evolved into a chronic but treatable 
disease. Although HAART suppresses viral replication and partially reconstitutes both CD4+ 
T cell numbers [139] and T cell immune responses to opportunistic infections, it cannot 
restore effective HIV specific T cell responses [140], resulting in a rapid rebound of HIV-1 
replication upon treatment interruption [141]. This implies that infected individuals are 
bound to lifelong treatment, imposing a high burden in terms of adherence, costs and the 
risk of drug related metabolic disorders [142]. Therefore, therapeutic vaccination has 
emerged as an option to boost and improve the cellular immune responses in infected 
individuals [143]. This concept is supported by increasing evidence that strong HIV-1 
specific CD4+ helper T cells and CD8+ CTLs are responsible for viral control both in 
macaques [144] and humans [145]. During acute infection CD8+ T cell responses contribute 
to control of the initial viraemia peak. However, in most infected subjects, this CD8+ T cell 
response loses its efficacy during chronic infection. This is due to a high mutation rate of the 
virus, the absence of proliferative and highly functional CD4+ T cells [145, 146] and the 
appearance of impaired or apoptotic HIV-specific CD8 T cells [147]. Clearly, the major 
challenge for therapeutic vaccination is to elicit strong CD4+ and CD8+ responses that would 
allow stopping of HAART. In vitro modulation of DCs to efficiently present target antigens 
to elicit cellular immune responses has been shown to be a promising strategy in cancer 
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immunotherapy [148], which constituted a model for development of similar HIV 
immunotherapies. 
5.2. Dendritic cells 
DCs are the sentinels of the immune system, bridging innate and adaptive immunity, in 
response to pathogens crossing the mucosal or dermal barrier. Immature DCs (iDCs) 
continuously sample their environment and take up autologous and foreign antigens [149]. 
They undergo maturation in response to signals that originate from pathogen-associated 
molecular patterns (PAMPs). These PAMPs activate a set of pattern recognition receptors 
(PRRs) such as Toll like receptors (TLRs), nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs), C-lectin receptors (CLRs) and retinoic acid-inducible gene 
protein (RIG)- like receptors (RLRs). Triggering of PPR results in an increased expression of 
major histocompatibility complex I and II (MHC I and MHC II), co-stimulatory molecules 
(CD80 and CD86) as well as secretion of T cell stimulatory cytokines (e.g. IL-12). During this 
maturation process DCs lose their ability to take up antigens and chemokine receptors (e.g. 
CCR7) are up-regulated in order to promote their migration to lymph nodes. Mature DCs 
process endogenous antigens via proteasome into 8-9 amino-acid peptides which are then 
loaded on MHC I and presented to CD8+ T cells. Exogenous antigens are processed via the 
endolysosome into longer peptides to be load onto MHC II for presentation to CD4+ T cells. 
The capacity of DCs to present exogenous antigens also via MHC I pathway (i.e. cross 
presentation), distinguishes them from other APCs, such as macrophages and B cells. To 
stimulate effective T cell responses, peptide-MHC complex on DCs should interact with T cell 
receptors (TCR). This is accompanied by binding of co-stimulatory molecules on DCs with 
CD28 present on T cells (figure 3). Finally, produced cytokines determine the differentiation of 
the effector cells into Th1, Th2 or CTL [150]. The latter is achieved after DCs’ licensing by the 
interaction of CD40 on the mature DCs with CD40L expressed on CD4+ T cells. IL-4 secretion 
promotes CD4+ Th2 cells, stimulating the production of antibody producing B cells. IL-12 
promotes CD4+ Th1 cells, providing help to CTL to kill infected cells. Secretion of IL-10 has a 
negative impact on Th1 or Th2 cells and induces immune tolerance. Licensed DCs also induce 
differentiation of CD8+ T cells into CTL via peptide-MHC I complex and promote survival of 
CD8+ T cells via co-stimulation through CD137L (4-1BBL) [151]. 
Roughly five DC subsets can be distinguished [152]. Classical or tissue resident DCs are 
located in lymphoid organs such as spleen and lymph nodes. Migratory DCs, found in non-
lymphoid organs such as skin, intestines and lungs, sample their environment and migrate 
to lymph nodes to present tissue derived antigen to T cells. Langerhans cells reside in the 
multi-layerd epithelium of the skin, oral and genital surfaces. Plasmacytoid DCs (pDCs) and 
myeloid or monocyte-derived DCs may be present in various tissues, yet they mainly 
circulate in the blood. pDCs are known as major producers of type I interferons (IFNs) in 
response to virus-associated molecules such as single-stranded (ss) RNA and unmethylated 
cytosine-phosphate-guanine (CpG)-rich DNA that trigger TLR7 and TLR9, respectively 
[153]. Myeloid DCs represent the major fraction of APCs in the blood that responds to TLR 
ligation by producing IL-12 [154]. Noteworthy, the APC function of DCs is impaired by 
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HIV, which could contribute to the dysfunction of HIV specific T cell responses since 
maturation of DCs and IL-12 secretion are diminished, thereby suppressing T cell responses 
[155]. HIV-infected DCs preferably secrete IL-10 thus limiting T cell proliferation and 
activation and rather induce tolerance [156]. HIV-1 infected DCs also act as a Trojan horse to 
infect new T cells by promoting tolerance of T cells to HIV-1 [157]. 
 
Figure 3. Differentiation process of dendritic cells. Immature DCs take up antigens. Activation of PPRs 
results in the differentiation towards mature DCs. The co-stimulatory molecules (B7-1, and B7-2) are 
overexpressed and the expression of the lymph node homing receptor CCR7 is induced. Mature DCs 
migrate to the draining lymph node, where they present antigens to cognate CD4+ T cells. Cross-linking 
CD40 on the DCs by CD40L expressed on the antigen-activated CD4+ T cell, induces the mature DCs to 
differentiate further, a process known as licensing. Licensed DCs up-regulate additional cell surface 
proteins, such as CD137L. The licensed DCs now present antigens to cognate CD8+ T cells. CD137L–
mediated co-stimulation through CD137 on the antigen-activated CD8+ T cells enhances the survival and 
proliferative capacity of the activated CD8+ T cells.  
5.3. HIV-1 antigen loaded dendritic cells tested in clinical trails 
To obtain a large population of DCs to be used in immunotherapy, DCs are derived from 
blood monocytes that are cultured in the presence of granulocyte and macrophage colony 
stimulation factor (GM-CSF) and IL-4 [158, 159]. Various approaches for loading DCs with 
antigens have been applied. They include the use of inactivated virus [104, 160], 
recombinant viral proteins [107, 161-163], peptides [101, 164], DNA [165-167] and mRNA 
[168-172]. After loading, DCs are matured using various maturation cocktails composed of 
cytokines (such as type 1 (α,β) or type 2 (γ) interferons, TNF-α, IL-6) prostaglandines (PG), 
TLR ligands, T cell derived products (CD40L) or small interfering RNA (siRNA) against 
suppressors of cytokine signaling (SOCS)-1 [98, 151].  
To this date at least ten DC-based immunotherapeutic vaccine trials (table 2) have been 
tested in infected individuals (recently reviewed by García and Routy [173]. Kundu et al. 
were the first to perform a human clinical trial, in which treatment-naïve HIV infected 
individuals were vaccinated with protein or peptides pulsed autologous DCs [107]. The 
vaccine was well tolerated and resulted in an increase of HIV specific CD8+ T cell response 
in 3 out of 6 individuals, but no effect on viral load was observed. Three other clinical trials 
tested peptides pulsed DCs [101, 105, 106]. In two of these trials an increase in HIV-specific 
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T cell responses in the absence of virological responses was shown [101, 105], whereas in the 
third study a transient decrease in viral load was found in 50% of vaccinated individuals 
[106]. Lu et al. were the first to demonstrate in vivo that a vaccine made of autologous 
monocyte-derived DCs, pulsed with autologous, aldithriol-2-inactivated HIV-1 was capable 
of inducing HIV-1-specific T cell responses. Moreover, there was an 80% decrease in plasma 
viral load levels over the first 112 days after vaccination. A prolonged suppression of viral 
load (of more than 90%) was seen for at least 1 year after vaccination in 8 out of 19 
vaccinated patients. This suppression of viral load correlated with HIV-1-specific IL-2 and 
IFN-γ expressing CD4+ T cells and with HIV-1 Gag-specific perforin-expressing CD8+ 
effector cells [108]. Unfortunately, the lack of a control group does not allow a proper 
evaluation of the results obtained. The group of García et al. performed two clinical trials 
with autologous DCs pulsed with heat-inactivated virus [103, 104]. In a double blind 
placebo controlled study with a similar setup as Lu et al., García et al. observed a small but 
significant decrease in viral loads for at least 48 weeks, concomitant with a weak increase in 
HIV-1 specific T cell responses in therapy naïve HIV infected individuals [103]. Another 
study performed by the same group in HAART treated patients showed a lengthening of 
the rebound after therapy interruption and a moderate increase in HIV specific T cell 




Vaccine strategy Subjects Clinical trial outcome 
Inactivated 
virus 
DCs pulsed with 
autologous AT2 
inactivated virus (109) 
Untreated 
patients (n= 18) 
Suppression of viral load was 
correlated with HIV specific IL-2 
or IFN-γ producing CD4+ T cells 
and perforin producing CD8+ 
effector T cells. [108] 
DCs pulsed with 
autologous heat 
inactivated virus (106) 
HAART treated 




Lengthening of viral rebound 
correlated with numbers of HIV-
specific proliferative CD4+ and 
CD8+ T cells. [104] 
DCs pulsed with 
autologous heat 
inactivated virus (109) 
Untreated 
patients (n= 18) 
Inverse correlation between 
decrease in viral load and HIV-
specific T cell responses. [103] 
Peptides DCs pulsed with Gag, 
Pol and Env peptides 
Untreated 
patients (n= 6) 
In 3/6 cases Env-specific and 
proliferative immune responses 
were observed. [107] 
DCs pulsed with HLA 
A*0201 binding epitopes 
in Gag, Nef and Env 
HAART treated 
patients  followed 
by therapy 
interruption (n=4)
In 2/4 patients moderate CD8+ T 
cell responses were observed. No 
lower viral setpoints after 
therapy interruption. [105] 
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Form of 
antigen 
Vaccine strategy Subjects Clinical trial outcome 
DCs pulsed with HLA 
A*0201 binding epitopes 
in Gag, Pol and Env 
HAART treated 
patients  (n=18) 
Increase in CTL responses against 
vaccine epitopes. [101] 
DCs pulsed with HLA 
A*0201 binding epitopes 
in Gag, Pol, Env, Vpu 
and Vif and Th epitopes 
in Gag and Env 
Untreated 
patients (n= 12) 
Generation of new T cell 
responses despite high viral 
loads. [106] 
DNA ALVAC pulsed DCs  vs 
AlVAC alone 
HAART treated 




No differences in T cell responses 
against HIV antigens. Did not 
lower VL setpoint after therapy 
interruption. [102] 





No lowering of viral setpoint 
after vaccination, but VL rebound 
was delayed. [177] 
mRNA Ex vivo electroporated 
DCs with mRNA 
encoding CD40L and 
autologous HIV proteins 
(Gag, Ref, Nef, Vpr) 
HAART treated 
patients  (n=10) 
HIV specific proliferative 
immune responses preferentially 
targeted to CD8+ T cells. 
Correlation with viral control 
during therapy interruption. 
[109] 
Ex vivo electroporated 
DCs with mRNA and 
autologous HIV proteins 
(Gag, Tat, Rev, Nef)  
HAART treated 
patients (n=6) 
Breadth of IFN-γ response and T-
cell proliferation were correlated 
with CD4+ and CD8+ 
polyfunctional T-cell responses. 
Autologous CD8+ T cells 
inhibited HIV superinfection in 
vitro. [176] 
Ex vivo electroporated 
DCs with mRNA and 
autologous HIV proteins 






Induced or enhanced CD4+ and 
CD8+ T cell responses specific for 
the vaccine antigens. [175] 
Table 2. Overview of therapeutic DC-based clinical trials. 
Nucleic acids are also used as a source of antigens in DC-based immunotherapies. Phase I 
and II clinical trials were conducted to evaluate the potential of a canarypox HIV-vaccine 
(ALVAC), containing DNA encoding Env, Gag as well as parts of Nef and Pol to either 
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directly vaccinate HAART-treated patient or ex vivo load autologous DCs. The results 
obtained did not demonstrate clear differences in the immunological or virological outcome 
and a control group was lacking [102]. In a very recent study, DNA encoding HIV proteins 
was complexed with polymers and topically administrated with a patch method named 
DermaPrep [174]. The results showed that vaccination induced new HIV-specific immune 
responses in HAART treated patients. Moreover, a better control of viral replication during 
treatment interruption was observed [167]. DCs loaded with mRNA have also been tested in 
clinical trials. Routy et al. reported the results of a trial in which HAART-treated patients 
received autologous DCs ex vivo electroporated with mRNA encoding autologous HIV 
sequences and CD40L [173]. This pilot study showed CD8+ T cells specific for the presented 
HIV antigen were preferentially targeted. Two other clinical trials employing autologous 
DCs electroporated ex vivo with mRNA encoding Tat, Rev, Nef and Gag were recently 
concluded [175, 176]. Both studies showed that vaccine-specific CD4+ and CD8+ T cell 
responses were enhanced. In one study vaccinated individuals interrupted treatment. Six 
out of 17 individuals remained off therapy 96 weeks after cessation [175]. 
One should keep in mind, however, that ex vivo manipulation of DCs is a complex 
personalized vaccination procedure, which prevents its accessibility to large numbers of 
patients. Therefore, there is a constant need for new approaches that could target DCs 
directly in vivo. In the following paragraphs we will discuss various non-viral delivery 
approaches which promote antigen uptake by DCs and induce potent immune responses. 
6. The way forward: Antigen delivery by non-viral carriers 
Even though viral vectors are generally considered more efficient, non-viral delivery 
vehicles receive increasing attention since they are safer, more versatile, easier to prepare 
and hence more accessible for up-scaling [178]. In addition, they allow delivery of larger 
quantities of antigens. Importantly, encapsulation protects antigens from their environment 
and therefore permits a prolonged release of antigens in tissues or particular cells [179]. 
The usual size of particulate vaccines, ranging from a few hundred nanometers to a few 
microns, is ideal for uptake by DCs [180]. Moreover, the nature of non-viral carriers 
allows their functionalization with moieties permitting specific targeting to DCs. 
Additionally they allow co-delivery of immunostimulatory molecules which can direct 
the immune system toward the humoral or cellular arm [181]. The simultaneous delivery 
of antigens and immune-stimulators to the same DC is a feature which has been reported 
to significantly augment the strength of the induced adaptive immune responses [182-
184]. In the following paragraphs we will discuss different lipid- and polymer-based 
carrier systems employed to deliver proteins and nucleic acids relevant for HIV-specific 
immunotherapy (table 3). 
6.1. Choice of antigen 
Peptides, proteins or nucleic acids (DNA or RNA) have been used as a source of antigen in 
the majority of therapeutic vaccination strategies. Each of them comes with specific 
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characteristics in terms of safety, stability, potential to cover antigenic variability, 
requirements for delivery and nature of the immune response induced [185]. Recombinant 
proteins or peptides utilized as subunit vaccines are safe and simple forms of antigens. 
However, their production at clinical grade quality is very expensive. As a consequence, 
only one or a few antigenic variants can be produced at an affordable price. Moreover, they 
are susceptible to pre-mature proteolytic degradation. Since DCs recognize them as 
exogenous antigens, they are preferentially presented in a MHC class II context [143] and to 
a lesser extent onto MHC I molecules via cross-presentation [180]. Therefore, they will not 
induce strong and broad CD8+ T cell responses, which are considered as a prerequisite for a 
therapeutic vaccine. These limitations can partially be resolved by their encapsulation. 
Encapsulation protects proteins and peptides from being prematurely degraded by 
proteolytic enzymes. Additionally, particulate antigen delivery favors cross-presentation 
thereby enhancing CD8+ T cell responses [186, 187]. In the context of HIV immunotherapy, 
however, the use of proteins as antigens is not ideal since HIV generates escape variants 
during the course of infection which remain present as a latent reservoir in cells [188]. With 
the technology available, it is not feasible to produce hundreds of variants of the same 









Proteins FDA approved, induction of specific 
antibodies and Th1 cellular responses 
Harsh preparation 






Induction of both Th1 and Th2 
responses. Easy to tailor with 
immunostimulators. Stability and 
release kinetics correlate with a 





Protect nucleic acids, facilitate escape 
from the endosomal compartment. 
Strong electrostatic 
interactions may 
hamper release of 






Good protection of antigens, facilitate 
intracellular uptake. Induction of 




Protect nucleic acids, facilitate escape 
from the endosomal compartment. 
Might aggregation in 
the presence of  serum 
Table 3. Advantages and disadvantages of different non-viral delivery systems. 
Nucleic acids, such a plasmid DNA (pDNA) or messenger RNA (mRNA), encoding viral 
proteins, can more easily cover the wide range of viral quasi species [189, 190]. As compared 
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to pDNA, mRNA-based delivery may hold several advantages. First of all, mRNA is easier 
to engineer; there is no need for specific promoters and terminators to be present in the 
construct. Secondly, the synthesis of proteins encoded by mRNA is transient, which ensures 
a controlled antigen exposure [191]. Thirdly, in contrast to pDNA, mRNA does not need to 
cross the nuclear membrane to be effective and therefore offers the possibility to produce 
proteins in slow or non-dividing cells [192]. Furthermore, the use of mRNA excludes the risk 
of integration into the cell genome, eliminating possible insertional mutagenesis [189, 193]. For 
years, the application of mRNA has been hampered by a general believe that it is too labile to 
guarantee sufficient protein expression. Nowadays, however, mRNA vaccination strategies 
are being thoroughly investigated in the field of allergy [194, 195], cancer [193, 196-198] and 
HIV [109, 170, 171] immunotherapy. These studies mostly rely on the ex vivo electroporation of 
dendritic cells. We and others focus on complexing mRNA with cationic lipids and polymers 
(figure 4), which could protect mRNA. Moreover, we believe that complexing mRNA with 
cationic carriers might hold potential for their application in vivo. This approach could serve as 
an alternative for laborious ex vivo loading of DCs.  
 
Figure 4. Internalisation and intracellular trafficking of mRNA/cationic carrier complexes. Negatively 
charged mRNA is complexed with cationic carriers (lipid or polymer based). After endocytosis, 
complexes end up in endosomes, from where they should release their cargo mRNA into the cytoplasm 
to enable translation by ribosomes .Translated protein is either secreted or can directly be processed via 
proteaseome to be presented with MHC class I. Secreted protein can be taken up and promote 
presentation in a MHC class II way after cleavage in the endolysosomes. 
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6.2. Polymer-based antigen delivery systems 
Various polymers have been used to prepare nano- and micro- particles for antigen delivery. 
Here, we will focus on polymers that have shown to be promising in terms of 
immunotherapeutic vaccination. 
6.2.1. Polymers based on lactic acid (PLA) and glycolic acid (PLGA) 
The most studied polymers for antigen delivery in the context of vaccination are the 
biodegradable poly(D,L-lactide) (PLA) and poly(D,L-lactic-co-glycolic acid) (PLGA), which 
have been FDA approved for human use. These particles have mainly been evaluated for 
their potential to deliver proteins and peptides to DCs or macrophages with the aim to 
induce CD8+ cytotoxic T cell immune responses in the context of prophylactic vaccination. It 
has been demonstrated that PLGA particles are phagocytosed by APCs [199] and ensure 
prolonged antigen presentation by DCs [200]. Whereas empty PLGA particles do not 
influence the maturation status of DCs [201, 202], DC activation can be induced, if the PLGA 
polymer is employed to encapsulate TLR ligands (poly I:C, MPLA) or surface loaded with 
anti-CD40 antibodies clear activation of DCs was observed [203-205]. PLA particles carrying 
p24 protein have been shown to induce both mucosal antibody production as well as CTL 
responses [206, 207]. 
The main drawback of these polymers is that some antigens tend to aggregate during the 
encapsulation process. Moreover, the exposure of proteins to organic solvents, required to 
dissolve the polymer, makes them highly susceptible to denaturation leading to the loss of 
antigenic epitope recognition [208]. This can partially be overcome by adsorption of proteins 
on the particle surface [209, 210]. Additionally, a rather expensive up-scaling process and 
clean-up procedure to ensure sterile production constitute difficult obstacles [211]. Due to 
the harsh preparation process and the hydrophobic nature of PLGA and PLA, these carriers 
are not suitable for nucleic acids delivery [212-214]. 
6.2.2. Polyelectrolyte microcapsules 
Polyelectrolyte microcapsules (PeMCs) fabricated using a so-called layer-by-layer (LbL) 
technology are a relatively novel class of particles [215]. The process of their preparation is 
less harsh as compared to that of PLGA/PLA particles. A template containing an antigen 
and colloid nanoparticles is used as a sacrificial core. This core is coated with several 
bilayers of polymers of opposite charges. At the end of the procedure the template core is 
dissolved (figure 5). Since the encapsulation process is performed in a purely aqueous 
environment, minimal stress for a protein antigen is ensured. With appropriate choice of 
polymers, these particles can be fully biodegradable. De Koker et al. used ovalbumin as a 
model antigen and showed the benefit of antigen encapsulation in PeMCs to stimulate 
antigen presentation to T cells by murine bone marrow-derived DCs [186, 216].  
PeMCs containing p24 and poly I:C (TLR-3 ligand) have been shown to be promising as an 
HIV-1 immunotherapeutic vaccine. Both antigen and maturation stimulus could be 
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delivered in the same particle to DCs inducing maturation and stimulation of HIV-specific 
responses both in vitro and in vivo [184]. PeMCs were also used for the delivery of Gag-
peptides to APCs. These APCs could activate SIV-specific T cells in an ex vivo non-human 
primate model [217]. Immune responses could be further improved by sensitizing the 
PeMCs to enzymatic or reductive degradation upon cellular uptake, thereby assuring 
release of its cargo [218, 219]. 
PeMCs have been also employed to deliver pDNA [213, 220]. When considering their use for 
the delivery of mRNA, however, one should make sure that the preparation process is 
rigorously RNase-free, which might present a challenge.  
 
Figure 5. Preparation of polyelectrolyte microcapsule [186]. (a) In the first step an antigen (yellow) of 
interest is mixed with colloid nanoparticles (grey) to form a core template. (b) In the next step a layer of 
negatively charged polymer is deposited (blue). The non-adsorbed polymer is removed by washing. 
This is followed by applying a positively charged polymer (red) and another washing step. (c) When 
the desired number of polyelectrolyte layers is obtained, the core is dissolved. 
6.2.3. Polyethyleneimine-based polyplexes 
Polyethyleneimine (PEI) has been extensively used to deliver pDNA and siRNA to cells 
[221-223]. PEI consists of repeating units that contain two carbon atoms and a protonatable 
nitrogen atom. It exists in a linear or branched conformation (figure 6), both appearing in a 
broad range of molecular weights. PEI can efficiently bind pDNA to form so-called 
polyplexes. The linear form has been shown to release complexed pDNA more easily than 
the more stable branched form and thus results in higher transfection efficiencies [224]. The 
net positive charge of the polyplexes promotes their adhesion to the overall negative charge 
of the cellular membrane and facilitates their uptake. The protonatable units of PEI have a 
buffering capacity resulting in an influx of hydrogen ions into the endosomes upon polyplex 
uptake. Due to osmotic pressure thus building up, the endosomes are disrupted resulting in 
complex release into the cytosol [222, 225]. This mechanism of escape from the endosomes is 
called the proton sponge mechanism [226]. 
The group of Lisziewicz developed a therapeutic HIV vaccine, DermaVir, consisting of PEI-
mannose complexed with pDNA encoding several HIV-1 antigens [227]. The vaccine was 
administered using a patch (DermaVir Patch) and was meant to target Langerhans cells 
(LCs) [174]. The vaccine induced specific and long lasting immune responses resulting in  
reduced viral load in SIV-infected macaques [228]. The safety of the vaccine formulation and 
of the delivery method was demonstrated in a phase I clinical trial in humans. A phase II 
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clinical trial started in 2009 and aims at evaluating immunogenicity and efficacy of the 
vaccine in treatment-naïve and HAART-treated patients [229, 230]. 
 
Figure 6. Structures of polyethyleneimine: (a) Linear backbone. (b) Branched backbone. 
The main drawback of using PEI is its toxicity and non-specific interactions with cellular 
compartments. Another challenge is the aggregation of polyplexes in the presence of serum.  
Rejman et al. reported that complexes made of mRNA and cationic lipids are much more 
efficient in transfecting different cell lines than PEI polyplexes. The authors suggest that this 
was likely due to the strong affinity of the polymer to mRNA impeding the release of the 
nucleic acid from the complexes. [191]. Bettinger et al. tested the potency of different protein 
derivatives for the delivery of mRNA. They demonstrated that complexing mRNA with 
short peptides results in better transfection efficiencies, likely due to a weaker electrostatic 
interaction with the nucleic acid. It should be noted, however, that the expression levels 
obtained were in general very low [192]. 
6.3. Lipid-based antigen delivery systems 
6.3.1. Liposomes 
Liposomes are spherical entities consisting of a phospholipid bilayer and an aqueous inner 
compartment. They have been used for drug delivery to treat cancer and infectious diseases. 
Until now, few liposomal formulations reached the pharmaceutical market of the U.S.A. 
Liposomes have been also employed to deliver antigens [231]. Given the liposome structure, 
the antigen can be encapsulated in its core (hydrophilic molecules) or accommodated within 
the lipid bilayer (hydrophobic molecules) [232]. It has been demonstrated that the lipid 
composition determines the immunogenicity of liposomes. For example, the incorporation 
of cationic lipids has been shown to elicit elevated CTL responses compared to neutral or 
anionic lipids [233]. Liposomal particles can be modified with specific ligands or antibodies 
to improve the uptake or to enhance/skew the immune response. Virosomes or virus like 
particles that consist of functional viral envelope proteins, anchored in a lipid membrane, 
have proven to be promising vaccine candidates [234]. Importantly, antigenic proteins 
encapsulated in liposomes can elicit both MHC I and II mediated immune responses as 
demonstrated by Zheng et al. [235]. These authors showed that HIV-1 Gag, Pol and Env 
proteins delivered to DCs by cationic liposomes induced stimulation of HIV-1 specific CD8+ 
T cell responses. This was not observed when DCs were pulsed with the soluble proteins. It 
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has been reported recently that mice immunized with Gag protein encapsulated in 
liposomes functionalized with lipid A induced both humoral and cellular immunity [236]. 
Another strategy to increase immunogenic potential of liposomal formulations involves the 
use of so-called lipopeptides. These structures consist of lipids linked to peptides that 
contain potential CD4+ and CD8+ T cell epitopes. These vaccines aim at the induction of 
strong T cell responses in HIV-1 infected patients [237-239]. Currently, a lipopeptide-pulsed 
DC vaccine is under evaluation in a phase I/II clinical trial in HAART-treated patients 
chronically infected with HIV-1 [240]. 
6.3.2 Cationic lipid based lipoplexes 
The combination of positively charged lipids and negatively charged nucleic acids results in 
spontaneous formation of complexes called lipoplexes (figure 7c). These systems typically 
consist of two lipid species: a cationic lipid (such as DOTAP - 1,2-dioleoyl-3-
trimethylammonium-propane) and a helper lipid with long unsaturated fatty acid chains 
(such as DOPE - dioleoylphosphatidylethanolamine) (figure 7). New cationic lipids are 
being synthesized almost daily aiming at introducing additional positive charges and 
reducing toxicity. Helper lipids are introduced to facilitate endosomal escape of these 
complexes [241]. 
The positive charge of lipoplexes promotes their cellular uptake, which was found to occur 
via clathrin-dependent and independent endocytosis [243-245]. The route of lipoplex uptake 
is determined by their size, chemical nature of the lipids and the cell line. After being 
internalised, the lipoplexes are located in endosomes. Escape from these compartments 
probably occurs via a mechanism proposed by Xu and Szoka [246]. It implies formation of 
neutral molecular pairs of lipoplex-derived cationic lipids and negatively charged 
phospholipids present in the endosomal membrane, eventually leading to release of the 
nucleic acid into the cytoplasm. 
 
Figure 7. Chemical structures of DOTAP, cationic lipid, and DOPE, neutral helper lipid, used to form 
lipoplexes [213, 242]. DOTAP (a) and DOPE (b) contain a hydrophilic head group, a glycerol linker 
and two hydrophobic fatty acid chains. (c) Schematic representation of a lipoplex containing nucleic 
acids (blue) stabilized by bilayer of lipids: hydrophilic groups (red), hydrophobic fatty acid chain 
(grey). 
 Immunodeficiency 50 
Lipoplexes are mainly used to transfect primary cells or cell lines in vitro. However, since the 
rise of DNA vaccines, cationic lipids are considered as a versatile method to replace the 
hazardous viral vectors. In mice DNA lipoplexes have been shown to induce antitumor 
activity [247] and both antibody and Th1 cellular responses against hepatitis C virus [248, 
249]. In the late eighties the first transfection with mRNA-lipoplexes was performed [250]. 
Generally it is established that mRNA transfection using non-viral cationic carriers is more 
efficient with cationic lipids than with cationic polymers [191, 192, 251, 252]. For both types 
of mRNA complexes the onset of protein expression was faster, but also lasted shorter than 
that produced by pDNA-complexes [191, 252]. The potential of mRNA-lipoplexes as an anti-
cancer or influenza vaccine dates back to the nineties [253, 254]. Since then most anti-cancer 
and anti-virus immunotherapies have been focused on the ex vivo loading of DCs mainly by 
means of electroporation [109, 196, 198, 255, 256]. 
One of the most serious challenges of the use of lipoplexes is the extrapolation from the in 
vitro to the in vivo situation. Optimal transfection conditions are maintained in vitro, while in 
vivo lipoplexes encounter serum proteins causing their aggregation [257]. Depending on the 
target cells or tissue, this aggregation can either negatively or positively affect the uptake of 
the lipoplexes [258, 259]. Additional coating of the lipoplexes with polyethyleneglycol (PEG) 
can prevent the formation of aggregates [260], yet brings along other problems. Concerns 
have been raised that PEGylation of lipoplexes may be unfavorable in the context of 
vaccination as this could inhibit uptake of nanoparticles by APCs and negatively interfere 
with the release of complexes from the endosomal compartment [213]. However, a study 
performed by Singh and colleagues demonstrated that subcutaneous immunization of 
rabbits with PEGylated lipoplexes carrying a synthetic gp41 epitope of HIV-1 induced two 
times higher immune responses and prolonged persistence of antibodies than liposomes 
carrying epitopes without PEG moieties [261].  
6.4. Targeting of DCs 
Conceptually, particulate vaccines mimic the particulate nature of pathogens, including the 
size (nano- to micro-meter range), which facilitates their uptake by APCs. The actual size of 
the particles influences the uptake mechanism by APCs and the way of antigen 
presentation. Generally, larger particles are predominantly internalised via phagocytosis or 
macropinocytosis, while smaller particles are taken up by other endocytic mechanisms [262-
264]. Internalisation through phagocytosis is known to lead to antigen cross-presentation in 
DCs [265, 266]. This emphasizes the enhanced potential of particulate antigen delivery to 
induce cellular immune responses as compared to soluble antigens, which are poorly cross-
presented and preferentially presented via the MHC class II pathway. 
Most nano- or microparticles can be functionalized with ligands or antibodies directed 
against cell surface receptors to target specific tissues or cells [267]. DCs express lectin-like 
receptors such as mannose receptor, DEC-205 and DC-SIGN which are believed to be 
involved in the phagocytosis of pathogens [268]. One way of increasing or promoting 
particle uptake by DCs is the attachment of mannose groups recognized by the mannose 
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receptors present on DCs and macrophages. This has been shown to increase transfection 
efficiency of DNA-based vaccines [269, 270], antigen presentation following protein delivery 
[271] and the induction of cellular T cell responses in cancer and HIV immunotherapeutic 
strategies using lipoplexes and polyplexes [228, 270]. Another way of targeting is the use of 
ligands or antibodies directed against DEC-205 or DC-SIGN, which have shown potential to 
improve antigen uptake by immature and mature DCs [272-275]. It should be kept in mind, 
however, that attaching the desired ligand or protein is not always a straightforward 
process. The engraftment of chelator lipids on the surface of liposomes or lipoplexes, such as 
histidine tags, is crucial to ensure the functionality of the coupled target molecule [276-278]. 
In this context, the use of nanobodies directed against DCs could be of particular interest as 
they are mostly generated with a histidine tag for purification purposes. Alternatively, 
ligands could also be linked to liposomes via palmitoylation of the ligand [279]. 
In summary, targeting of particles may not only enhance efficacy but also the specificity of 
interaction with the surface receptors on DCs [179]. Moreover, coupling of specific adjuvants 
(e.g. TLR ligands), with the aim to promote the desired immune response, can also 
positively influence the uptake by DCs [280]. 
6.5. Co-delivery of antigens and adjuvants to improve immunogenicity of DCs 
Although particulate antigen delivery improves antigen uptake and presentation by DCs, 
most particles are not immunogenic by themselves. This offers a possibility to use a specific 
adjuvant that can skew towards the desired type of immune responses [187]. Despite some 
positive results in animal models, one should be aware of the toxicity of potential 
immunomodulators in humans, that jeopardizes their clinical use [281]. Aluminum salts 
(referred to as alum) are the oldest and most widely used adjuvants for human vaccines. It 
has been shown that antigens can be precipitated with alum to form colloid particles, 
creating a depot effect after vaccination, that elicits strong humoral immune responses [282]. 
These results, together with further observations clearly showed that the physical linkage of 
antigen and immunomodulator is crucial to induce strong immune responses [182, 183, 283]. 
Immunostimulating complexes (ISCOMs) are another interesting delievery system. It is a 
sort of liposomal delivery vehicle with a built-in adjuvant. They are composed of a protein 
antigen, phosopholipids and the saponin Quil A adjuvant, derived from the bark of the 
Quillaja saponaria, a South American tree. It has been demonstrated that the use of ISCOMs 
improves CTL responses of influenza virus based vaccines [284, 285]. ISCOM-based vaccines 
have been tested in animal models and in clinical trials against cancer [286] and viral 
infections [287-289] [290, 291]. In all studies satisfactory safety and tolerance were shown 
and both humoral and cellular responses were induced.  
Several studies have reported the use of ISCOMs as a system to deliver HIV or SIV antigens. 
In non-human primate models, incorporation of HIV or SIV peptides into ISCOMs has been 
shown to induce protective immunity [288, 292, 293]. Moreover, studies in mice 
demonstrated that ISCOMs can be used to elicit immune responses against HIV-1 antigens 
[287]. To generate mucosal immunity, Koopman and colleagues immunized rhesus 
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maquaqes intranasally or via lymph nodes with HIV-1 peptides formulated into PR8-Flu 
ISCOMs [294]. Intranodal injection of these ISCOMs induced strong systemic and mucosal 
immune responses. In contrast, intranasal application resulted in very weak responses. 
Currently, ISCOM-based vaccines have been approved for veterinary use and are 
undergoing clinical trials for human use [295]. 
As described before, for an optimal immune response it is crucial that DCs, besides actively 
taking up the antigen, undergo activation and maturation to stimulate effective T cell 
responses. Ligands mimicking PAMPs that can target PPRs are therefore of potential 
interest. Extracellular and intracellular PPRs are divided into four groups: TLRs, NLRs, 
CLRs and RLRs [181]. Depending on the receptor that is triggered, DCs produce and secrete 
various sets of cytokines, determining the type of immune response [296]. Moreover, the 
incorporation of TLR ligands promotes phagocytosis of APCs [280]. TLRs represent the 
majority of PPRs studied in the development of effective adjuvants [281]. TLRs can be 
divided into two groups: the surface bound receptors (TLR 1, 2, 4, 5, 6) and the intracellular 
receptors present in the endosomes (TLR 3, 7, 8, 9) (table 4). 
 
TLR TLR ligand DC subset Effect of activation
1:2 Triacyl lipoproteins Mo-DCs, 
myeloid DCs 
Upregulation of CCR7, IL-6, IL-10, IL-
12p70,TNF-α 
2 Lipoproteins Mo-DCs, 
myeloid DCs 
Upregulation of CCR7, IL-6, IL-10, IL-
12p70,TNF-α 




IFN-α/β activation and up-regulation IL-
12p70 
4 Lipopolysaccharide Mo-DCs, 
myeloid DCs 
Upregulation of CD80, CD86, CD83, CCR7.  
Secretion of  IL-6, IL-8, IL-10, IL-12p70, IFN-
β
5 Flagellin Mo-DCs, 
myeloid DCs 
Upregulation of CD80, CD86, CD83, CCR7.  
Secretion IFN-α/β , IL-1 , TNF-α, IL-8, IL-
12p40 
6:2 Triacyl lipoproteins Mo-DCs, 
myeloid DCs 
Upregulation of CCR7, IL-6, IL-10, IL-
12p70,TNF-α 




Upregulation of CCR7,CD40, CD80 and 
CD86. Secretion of IL-12p70 (myeloid DCs). 
Secretion of IFN-α (pDCs). 
8 Single stranded 
mRNA 
Mo-DCs Increased TNF , IL-8, IL-12p40, MCP-1, 
CCL2, CCL3, CCL4, CCL5 
9 Double stranded 
DNA 
pDC Upregulation of CD40, CD80, CD86, CD83, 
HLA-DR, CCR7. Upregulation of IFN-α 
(very high), IFN-β (lower), IL-6, TNF-α  
(low), IL-8
Table 4. Overview of Toll like receptors (TLRs) with their ligands and effect of activation [297]. 
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The extracellular TLRs mainly recognize bacterial invaders, but also fungi and some 
enveloped viruses. Bacterial lipoproteins are recognized by the heterodimers TLR1:2 (triacyl 
lipoproteins) and TLR2:6 (diacyl lipoproteins). Liposomes engrafted with palmitoyl chain 
lipopeptides have been shown to up-regulate DC maturation markers in vitro [298]. 
Lipopolysaccharide (LPS), a gram negative bacterial carbohydrate, is recognized by TLR4. 
Recently, a phase I clinical trial has started evaluating the potential of autologous dendritic 
cells, ex vivo loaded with lipopeptides and activated with LPS, as an immunotherapy in HIV 
infected patients (NCT00796770). Lipopolysaccharide (LPS), a gram negative bacterial 
carbohydrate, is recognized by TLR4. Since the in vivo use of LPS for human purposes is not 
possible due to the risk of septic shocks, a derivative, monophosphoryl lipid A from 
Salmonella Minnesota referred to as MPLA, was proposed as a substitute. It has been shown 
to be less toxic than LPS and thus preferable for human vaccine applications. MPLA has 
been incorporated in PLGA particles and liposomes [299, 300]. Furthermore, MPLA is 
already used in combination with alum (AS04) as an adjuvant in Cervarix®, a human 
papilloma virus vaccine from GlaxoSmithKline. Another bacterial component, flagellin, is 
recognized by TLR5 and is also used as a potential adjuvant. Flagellin-related peptides 
containing a His-tag and incorporated in liposomes containing a tumor antigen, induced 
antitumor responses resulting in complete tumor regression in mice [278]. The advantage of 
flagellin is that it can be co-integrated as a protein into particulate vehicles or integrated as 
His-tagged peptides into liposomes. 
The intracellular TLRs specifically recognize nucleic acids and are of major importance to 
the recognition of double stranded DNA (dsDNA) from viral or bacterial intruders. TLR-9, 
only expressed in pDCs, recognizes unmethylated cytosine-phosphate-guanine (CpG) 
oligodeoxynucleotides (ODNs). CpG motifs were demonstrated to induce cell-mediated 
responses in vivo when incorporated into PLGA particles [301, 302], liposomes [303] and 
other microparticles [304]. All these studies reported enhanced Th1 biased immune 
responses. Viral single stranded RNA (ssRNA) is recognized by TLR7 (expressed by all DC 
subsets and B-cells) and TLR8 (expressed by macrophages, monocytes and myeloid DCs) 
[181]. Agonists used to trigger these receptors are the synthetic imidazoquinoline drug 
compounds imiquimod and resiquimod (R848) or polyuridylic acid (polyU). Only few 
studies so far have used TLR7/8 ligands for particulate antigen delivery. Johnston et al. 
demonstrated that the combination of TLR 7 ligand with liposomes increased the cellular 
immune responses against OVA protein in a mice model [305]. Another study reported that 
co-encapsulation of OVA antigen and polyU in PLA-DOTAP microparticles increased the 
antibody titers and numbers of IFN-γ secreting T cells [306]. Finally, the endosomal TLR3 
recognizes dsRNA, which can be mimicked by the synthetic polyinosinic:polycytidylic acid 
(poly I:C). This dsRNA analog is widely evaluated as a potential adjuvant since it strongly 
promotes the maturation of DCs [184, 204]. Furthermore, the combination of poly I:C with 
protein antigens encapsulated in either polymeric [183, 184, 307] or liposomal [308] particles 
favors enhanced Th1 immune responses. With regard to mRNA vaccination, the use of 
endosomal TLR ligands is problematic, since upon recognition by their receptor, high levels 
of type I interferon are produced leading to the activation of RNases [309, 310]. However, 
mRNA by itself can also trigger endosomal TLRs, implying the crucial importance of 
stabilizing the antigen encoding mRNA (reviewed by Tavernier et al.) [189]. 
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Another possibility to improve immunogenicity is the addition of co-stimulatory molecules. 
The addition of CD40L to DCs loaded with liposome-complexed HIV-1 proteins could 
prime HIV-1 specific CD8+ T cells in vitro [162]. Within the scope of mRNA transfection, 
mRNA encoding co-stimulatory molecules can be co-transfected with mRNA encoding an 
antigen, which has been shown to strongly enhance the capacity of electroporated DCs to 
stimulate HIV-specific T cell responses [311].  
7. Concluding remarks 
Ex vivo loading of DCs shows promising results as an immunotherapy for HIV and cancer. 
However, the currently applied strategy is not applicable on a large scale, especially in 
Africa where the largest incidence of HIV infections is observed. The use of particulate 
vehicles able to directly deliver the antigen of interest, be it proteins, peptides or nucleic 
acids,  into DCs in vivo is a very attractive concept. Different antigen formulations can be 
further tailored with targeting antibodies or immunomodulatory ligands to promote uptake 
by DCs and to trigger the desired type of immune response. In the context of HIV 
immunotherapy a large number of epitopes needs to cover a broad panel of quasi species. 
Therefore, mRNA-based vaccination strategies present an attractive option. In contrast to 
pDNA, mRNA needs to be delivered only into the cytoplasm and induces transient antigen 
expression without the risk of genomic insertion. Further research will be required for 
designing an optimal carrier system preferably comprising an adjuvant, necessary to 
achieve strong HIV-specific CTL responses with the ultimate goal to control viral replication 
in the absence of additional HAART therapy. 
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